# Beyond THC and CBD: Insights on Cannabis’s Non-Cannabinoid Compounds > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-non-cannabinoid-phytochemicals-review/ > **Published:** 2026-08-16T10:52:44-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T22:00:26-04:00 > **Clinical Summary:** Explore the cannabis non-cannabinoid phytochemicals review highlighting terpenes, flavonoids, and their preclinical activities shaping the entourage effect. --- CED Clinical Relevance #79 Clinical Evidence Update A systematic review searched Scopus, Google Scholar, and PubMed (January 2010 to May 2025), screened 187 articles, and synthesized 12 studies on the non-cannabinoid phytochemicals of Cannabis sativa, terpenes, flavonoids, phenolic compounds, and alkaloids, published in Plants (MDPI) in July 2026. It is the most current, focused synthesis of this literature and directly addresses the ‘entourage effect,’ a claim patients and clinicians encounter constantly. The entire evidence base is preclinical (in vitro and animal studies), so it is presented here as a careful evidence-mapping review rather than proof of any clinical effect. Clinical Insight | CED Clinic Patients frequently ask why one cannabis product ‘works differently’ than another with a similar THC or CBD percentage, and clinicians often have only the entourage effect as a loose answer. A newly published systematic review searched three databases for research on cannabis’s non-cannabinoid phytochemicals, terpenes, flavonoids, phenolic acids, and alkaloids, and synthesized 12 qualifying preclinical studies into a picture of how these compounds might shape a product’s effects. The review is useful precisely because it draws a clear line: consistent early laboratory signal for several biological activities, alongside an explicit acknowledgment that none of it has yet been tested in people. TerpenesFlavonoidsEntourage EffectPreclinical ResearchWhole-Plant Medicine Audience Patients curious about full-spectrum versus isolated cannabinoid products, cannabis clinicians who explain the entourage effect to patients, and primary care physicians fielding questions about why strain or formulation seems to matter Primary Topic A systematic review of the non-cannabinoid phytochemicals in Cannabis sativa, terpenes, flavonoids, phenolic compounds, and alkaloids, and their preclinical pharmacological activity, published in Plants (MDPI) in 2026 Source [Read the systematic review in Plants (MDPI)](https://doi.org/10.3390/plants15142142) Table of Contents - [Beyond THC and CBD: What a New Review Says About Cannabis’s Other Compounds](#Beyond_THC_and_CBD_What_a_New_Review_Says_About_Cannabis8217s_Other_Compounds) - [How to Read a Preclinical Review of Cannabis’s ‘Minor’ Compounds](#How_to_Read_a_Preclinical_Review_of_Cannabis8217s_8216Minor8217_Compounds)[A Four-Step Reading Frame](#A_Four-Step_Reading_Frame) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[Promising Lab Findings Are Not the Same as a Proven Benefit](#Promising_Lab_Findings_Are_Not_the_Same_as_a_Proven_Benefit) - [A Useful Reference for a Question Patients Ask Constantly](#A_Useful_Reference_for_a_Question_Patients_Ask_Constantly) - [A Fair, Precise Answer to a Common Question](#A_Fair_Precise_Answer_to_a_Common_Question) - [Twelve Studies, Zero Human Trials](#Twelve_Studies_Zero_Human_Trials) - [Specific, Testable Molecular Targets](#Specific_Testable_Molecular_Targets) - [Strain Variability Is a Real Manufacturing Problem](#Strain_Variability_Is_a_Real_Manufacturing_Problem) - [Precision Protects Consumers From Overclaiming](#Precision_Protects_Consumers_From_Overclaiming) - [A Clear Case for the Trials That Have Not Been Run](#A_Clear_Case_for_the_Trials_That_Have_Not_Been_Run) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## Beyond THC and CBD: What a New Review Says About Cannabis’s Other Compounds A systematic review searched three databases and narrowed 187 articles down to 12 qualifying studies on cannabis’s non-cannabinoid phytochemicals: terpenes, flavonoids, phenolic acids, and alkaloids. In cell and animal studies, several of these compounds showed anti-inflammatory, analgesic, anti-cancer, and antimicrobial activity, and appear to act on some of the same molecular targets as cannabinoids. None of this work has yet been tested in human clinical trials. What This Study Teaches Us This review maps out what is actually known, and not known, about the roughly 500 phytochemicals in Cannabis sativa that are not cannabinoids. It identifies which compound classes, terpenes and flavonoids, are best studied, names specific molecules with documented laboratory activity, such as beta-caryophyllene, myrcene, and cannflavin A and B, and lays out a plausible molecular basis for the entourage effect, while being explicit that the entire evidence base is preclinical. Why This Matters The entourage effect is one of the most commonly invoked, and most poorly sourced, explanations in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/). When patients or product marketing claim that ‘whole-plant’ extracts work better than isolated cannabinoids, clinicians need to know what specific evidence does and does not support that claim. This review is a useful primary-source anchor for that conversation, precisely because it draws a hard line between promising cell-and-animal findings and the current absence of human trial data on these compounds in isolation. Study Snapshot Study Type Systematic review of preclinical and mechanistic pharmacology literature (not a clinical trial or meta-analysis) Databases Searched Scopus, Google Scholar, and PubMed Search Window January 2010 to May 2025 Screening 187 articles initially retrieved; 12 met inclusion and exclusion criteria for full review Compound Classes Reviewed Terpenes (over 100 identified in C. sativa), flavonoids (about 20 identified), phenolic acids and spiro-phenols, and alkaloids (cannabisativine, anhydrocannabisativine) Best-Characterized Groups Terpenes (myrcene, limonene, linalool, alpha-pinene, beta-caryophyllene) and flavonoids (cannflavin A and B, apigenin, luteolin, kaempferol, quercetin) Nature of the Evidence All preclinical: in vitro cell assays and animal (mouse or rat) models. No human clinical trials of isolated non-cannabinoid compounds were identified. Proposed Mechanism The ‘entourage effect’: terpene-cannabinoid interaction at shared targets including [CB2 receptors](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/) and TRP channels, plus inhibition of fatty acid amide hydrolase (FAAH), which may raise endogenous anandamide levels Reported Preclinical Activities Anti-inflammatory, anti-cancer, anti-diabetic, analgesic, and antimicrobial activity across different compounds and models Authors’ Stated Limitation None of the reviewed non-cannabinoid compound studies have reached clinical trials; standardization, regulatory, and analytical-method barriers block clinical translation Journal Plants (Basel, Switzerland), MDPI Published July 11, 2026, Volume 15, Issue 14, Article 2142 DOI 10.3390/plants15142142 PMID 42514510 PMCID PMC13416479 Affiliations Sefako Makgatho Health Sciences University, Pretoria, South Africa Clinical Bottom Line A systematic review of the small preclinical literature on cannabis’s non-cannabinoid compounds, terpenes, flavonoids, phenolic acids, and alkaloids, found consistent early signal for anti-inflammatory, analgesic, anti-cancer, and antimicrobial activity in cell and animal models, and a plausible molecular basis for the entourage effect. None of it has been tested in human clinical trials, and the authors are explicit that clinical translation remains blocked by standardization, regulatory, and analytical-method challenges. What the Review Searched For and Found The authors searched Scopus, Google Scholar, and PubMed for literature on Cannabis sativa phytochemicals published between January 2010 and May 2025, using search terms built around non-cannabinoid compounds and their pharmacological activity. That search initially returned 187 articles. After applying inclusion and exclusion criteria, 12 studies qualified for the final review. The review organizes its findings around four non-cannabinoid compound classes: terpenes, flavonoids, phenolic compounds (including phenolic acids and spiro-phenols), and alkaloids. Terpenes: The Best-Characterized Group Over 100 distinct terpenes have been identified in Cannabis sativa, produced in the same glandular trichomes that make cannabinoids and responsible for much of the plant’s characteristic smell. The review highlights monoterpenes such as D-limonene, linalool, beta-myrcene, and alpha-pinene, and sesquiterpenes such as beta-caryophyllene. In the cited preclinical work, beta-caryophyllene binds directly to the CB2 cannabinoid receptor, myrcene has been associated with reduced IL-6 expression in inflammation models, and terpene blends including alpha-pinene showed antimicrobial activity against several bacterial genera in laboratory testing. Flavonoids and a Proposed Entourage Mechanism About 20 flavonoids have been identified in Cannabis sativa. Cannflavin A and B are unique to the plant and, in the cited cell studies, inhibited 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 while showing minimal inhibition of COX-1 and COX-2, a pattern the review links to a lower theoretical risk of the gastrointestinal side effects associated with traditional COX-inhibiting [anti-inflammatory drugs](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/). This has not been tested in patients. Other flavonoids identified in the plant, apigenin, luteolin, kaempferol, and quercetin, were studied mainly in cancer cell lines and animal tumor models. The review describes a proposed entourage mechanism in which [cannabinoids and terpenes](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) converge on shared targets, including TRP channels and [CB2 receptors](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/), and notes that CBD and some flavonoids may inhibit fatty acid amide hydrolase (FAAH), the enzyme that breaks down the body’s own endocannabinoid anandamide. Reported Preclinical Activities Across Compound Classes Across the 12 included studies, the review reports laboratory or animal-model signal for anti-inflammatory activity (beta-myrcene, cannflavin A and B), anti-cancer activity (quercetin-rich extracts, apigenin, kaempferol, and a cannflavin B analog called FBL-03G tested in pancreatic cancer models), anti-diabetic activity (flavonoid-rich extracts affecting glucose measures in rodent and cell models), analgesic activity (myrcene and limonene acting on adrenergic and pain-signaling pathways), and antimicrobial activity (several terpenes against Gram-positive and Gram-negative organisms). Every one of these findings comes from cell culture or animal-model experiments. None involved human participants, and none evaluated an isolated non-cannabinoid compound as a standalone treatment in people. Why This Hasn’t Reached Human Trials The review points to several concrete barriers to clinical translation. Non-cannabinoid compounds are typically present in low concentrations, and there is a lack of validated reference standards and analytical methods for identifying and quantifying them precisely, which complicates accurate dosing. Plant chemotype and cultivation method also matter: the review cites a comparison in which the flavonoid content of one cannabis strain, Carmagnola Cs, ran up to 25 percent higher than in another strain, Kompolti. Most existing human data comes from trials of whole-plant or full-spectrum extracts that combine cannabinoids and non-cannabinoids together, which the authors note makes it difficult to isolate the individual contribution of any single non-cannabinoid compound. What the Authors Themselves Concluded The authors conclude that non-cannabinoid phytochemicals are integral to the pharmacological complexity of Cannabis sativa and warrant further investigation as candidates for drug development, particularly in formulations designed to optimize whole-plant therapeutic effects. They call explicitly for further research into non-cannabinoid interactions, pharmacokinetics, and clinical efficacy, stating that such research is needed to understand whether the synergy they describe actually underlies the enhanced outcomes sometimes reported with full-spectrum extracts compared with isolated cannabinoids. How Strong Is This Evidence? This review has real value as an organizing effort: it applies a transparent, three-database search strategy with defined inclusion and exclusion criteria to a genuinely understudied fraction of the cannabis plant, and it ties scattered laboratory findings to a coherent proposed mechanism, shared molecular targets and FAAH inhibition, rather than presenting isolated, unconnected claims. Naming specific, verifiable compounds such as beta-caryophyllene, myrcene, and cannflavin A and B, rather than speaking only in generalities about ‘terpenes’ or ‘the entourage effect,’ makes the review’s claims easier for clinicians and researchers to trace back to their original sources. Where This Paper Deserves Skepticism The evidence base here is small and entirely preclinical. Only 12 studies were included out of 187 screened, and the review does not describe a formal risk-of-bias or quality-appraisal tool applied to those 12 studies, unlike systematic reviews of clinical trials. Every cited finding comes from in vitro cell assays or animal models, and dosing in those models does not translate directly to a human-relevant dose in an actual cannabis product. Because most existing human trials use whole-plant or full-spectrum extracts that combine cannabinoids and non-cannabinoids, the authors themselves acknowledge that no human study has isolated the effect of any single non-cannabinoid compound. Finally, phytochemical content varies meaningfully by strain and cultivation method, so a laboratory finding tied to one plant chemotype may not generalize to the product a given patient is actually using. What This Paper Does Not Show This review does not show that terpenes, flavonoids, or any other non-cannabinoid cannabis compound treats any human disease or symptom. It does not show that full-spectrum or whole-plant cannabis products outperform isolated cannabinoids in patients, since no human trial isolating these compounds was identified. It does not establish a safe or effective human dose for any of the terpenes or flavonoids discussed, since the cited data come from cell cultures and animal models using their own dosing conventions. It also does not resolve how much of any product’s terpene or flavonoid content survives extraction, formulation, and administration to reach a patient in a biologically active form. How This Fits With the Broader Clinical Conversation This review sits inside a much longer-running debate about the ‘entourage effect,’ a term first proposed by Mechoulam and Ben-Shabat in 1998 to describe synergistic interactions among cannabis compounds. The idea has since become a common marketing claim for full-spectrum products, often stated with far more confidence than the underlying evidence supports. What this review adds to that debate is not new proof of the entourage effect in patients, but a more organized accounting of which non-cannabinoid compounds have documented laboratory activity, which molecular targets they might share with cannabinoids, and how far the field still is from testing any of this directly in people. Dr. Caplan’s Take *I have spent more than 20 years practicing evidence-based [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), and ‘entourage effect’ is a phrase I hear used far more often than it is actually sourced. This review is useful to me precisely because it resists that temptation. It names specific compounds, beta-caryophyllene binding [CB2 receptors](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/), cannflavin A and B inhibiting inflammatory enzymes, myrcene’s association with reduced IL-6, and it is honest that every one of those findings comes from a dish or an animal model, not a patient.* *When a patient asks me whether a full-spectrum product will work better for them because of its terpene or flavonoid content, this review tells me I can talk about plausible mechanisms and promising early laboratory signal, but I cannot yet tell them that science has confirmed a clinical benefit from any specific non-cannabinoid compound. That distinction matters. It is not a reason to dismiss whole-plant formulations, which many patients report benefiting from, but it is a reason to be precise about what is mechanism, what is preclinical signal, and what remains, for now, unproven in humans.* What a Careful Reader Should Take Away A systematic review of a small preclinical literature found that several non-cannabinoid compounds in cannabis, terpenes and flavonoids in particular, show anti-inflammatory, analgesic, anti-cancer, and antimicrobial activity in cell and animal studies, and identified plausible shared molecular targets with cannabinoids that could explain an entourage effect. None of this has been tested in human clinical trials, and standardization, regulatory, and analytical barriers currently block that next step. Evidence Interpretation Guide ## How to Read a Preclinical Review of Cannabis’s ‘Minor’ Compounds A review that names specific bioactive compounds and describes shared molecular targets can sound like it is describing a proven mechanism. Four checks keep this review’s real, more limited contribution in view. ### A Four-Step Reading Frame **Check whether the evidence is preclinical or clinical**Every finding in this review comes from cell cultures or animal models. No human trial of an isolated non-cannabinoid compound was identified. **Separate named compounds from vague claims**The review names specific molecules, such as beta-caryophyllene and cannflavin A and B, which is more traceable than a general appeal to ‘terpenes’ or ‘the entourage effect.’ **Note how small the qualifying evidence base is**Only 12 studies met inclusion criteria out of 187 screened, and no formal risk-of-bias tool is described for those 12 studies. **Hold the authors’ own caveat**The authors state directly that clinical translation is blocked by standardization, regulatory, and analytical-method barriers, and that further pharmacokinetic and [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) is needed. The Research Question What pharmacological activity do the non-cannabinoid phytochemicals of Cannabis sativa, terpenes, flavonoids, phenolic compounds, and alkaloids, show in the existing scientific literature? The Patient Question Does the terpene or flavonoid content of my cannabis product give it a real, proven benefit beyond THC or CBD alone? The Bottom Line The evidence currently supports plausible laboratory-level mechanisms and preclinical activity for several non-cannabinoid compounds, but not a confirmed clinical benefit in humans, and rigorous human trials of these compounds have not yet been conducted. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview Eight perspectives keep a review naming specific bioactive compounds and molecular targets from being oversold as proof of a clinical entourage effect, or dismissed because the evidence is preclinical. #### Promising Lab Findings Are Not the Same as a Proven Benefit If you use a full-spectrum cannabis product and believe its terpene or flavonoid content is helping you, this review shows there is a plausible scientific basis for that idea, some of these compounds do show real biological activity in laboratory studies. It does not show that any specific terpene or flavonoid has been proven to help a human condition on its own. Your experience with a product is real to you, but it is not the same as clinical proof. Lens takeaway Treat entourage-effect marketing claims as plausible, not proven. #### A Useful Reference for a Question Patients Ask Constantly Cannabis clinicians are asked about the entourage effect routinely, often without a clear primary source to point to. This review offers named compounds and proposed mechanisms, CB2 binding, FAAH inhibition, shared TRP channel activity, that can ground that conversation in specifics rather than marketing language. It is equally important to communicate the limitation clearly: this is laboratory and animal evidence, not confirmation that any specific product formulation produces a specific clinical outcome. Lens takeaway Useful vocabulary for patient conversations, not yet a basis for specific formulation recommendations. #### A Fair, Precise Answer to a Common Question Primary care physicians increasingly field questions about full-spectrum versus isolated cannabinoid products from patients using cannabis medically or recreationally. This review supports a specific, honest answer: some non-cannabinoid compounds show early laboratory activity and a plausible mechanism for interacting with cannabinoids, but no compound has been tested in a human clinical trial in isolation. Lens takeaway A precise, evidence-based answer beats either blanket endorsement or blanket dismissal of whole-plant products. #### Twelve Studies, Zero Human Trials It is worth sitting with the numbers: 187 articles screened, 12 included, and not a single human trial of an isolated non-cannabinoid compound among them. That is a narrow evidentiary base for a mechanism as widely cited as the entourage effect. No risk-of-bias or quality-appraisal tool is described for the 12 included studies, which is a notable gap compared with systematic reviews of clinical trial evidence. Lens takeaway Read the review as an evidence map of a young field, not as a settled scientific case. #### Specific, Testable Molecular Targets The review’s most concrete contribution is mechanistic: beta-caryophyllene binding CB2 receptors, terpene and cannabinoid convergence on TRP channels and adenosine and serotonin receptors, and FAAH inhibition by CBD and some flavonoids that could raise endogenous anandamide levels. These are specific, testable hypotheses, which is a meaningfully different, and more useful, starting point than a general claim that ‘the whole plant works better.’ Lens takeaway A concrete mechanistic framework worth testing directly, not yet a confirmed pathway in humans. #### Strain Variability Is a Real Manufacturing Problem The review’s citation of a roughly 25 percent difference in flavonoid content between two cannabis strains is a practical reminder that ‘full-spectrum’ is not a single, standardized thing. Two products labeled full-spectrum could differ meaningfully in their non-cannabinoid content. Combined with the lack of validated reference standards for minor phytochemicals, this makes consistent dosing of any specific non-cannabinoid compound difficult to guarantee at the product level today. Lens takeaway Formulation consistency for non-cannabinoid compounds remains an unresolved manufacturing challenge. #### Precision Protects Consumers From Overclaiming Marketing language describing full-spectrum products as scientifically proven to work better because of the entourage effect outruns what this review, or any current review, can support. Communicating this review’s actual finding, plausible mechanism and early laboratory signal, without clinical confirmation, protects consumers from paying a premium based on overstated claims. Lens takeaway Report entourage-effect claims with their actual evidentiary status, not as settled science. #### A Clear Case for the Trials That Have Not Been Run The authors’ call for further research into non-cannabinoid pharmacokinetics and clinical efficacy is a direct, actionable research priority, not boilerplate language, especially given how widely the entourage effect is invoked commercially. Developing validated analytical standards for minor cannabis phytochemicals would itself be a meaningful and fundable step toward the human trials this review says are still missing. Lens takeaway This review makes the case for funding both analytical-standards work and the human trials it says have not yet happened. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Beyond+THC+and+CBD%3A+What+a+New+Review+Says+About+Cannabis%27s+Other+Compounds&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-non-cannabinoid-phytochemicals-review%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-non-cannabinoid-phytochemicals-review%2F) [BlueSky](https://bsky.app/intent/compose?text=Beyond+THC+and+CBD%3A+What+a+New+Review+Says+About+Cannabis%27s+Other+Compounds%20https%3A%2F%2Fcedclinic.com%2Fcannabis-non-cannabinoid-phytochemicals-review%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Sanni O, Ogunrombi MO, Obi CL. The Pharmacological Activity of Non-Cannabinoid Phytochemicals in Cannabis sativa L.: A Systematic Review. Plants (Basel). 2026;15(14):2142. DOI: 10.3390/plants15142142. PMID: 42514510. PMCID: PMC13416479.](https://doi.org/10.3390/plants15142142) Related Reading at CED Clinic Continue exploring the evidence [Prenylated Apigenin Derivatives from Cannabis sativa L.: Isolation, Biosynthesis, and Anti-Cancer Activity](https://cedclinic.com/prenylated-apigenin-cannabis-research-isolation-biosynthesis/) A CED review of research isolating prenylated apigenin, one of the same flavonoids discussed in this broader non-cannabinoid phytochemical review, useful background on how individual cannabis flavonoids are studied. [Read the apigenin research review](https://cedclinic.com/prenylated-apigenin-cannabis-research-isolation-biosynthesis/) [Cannabis Extract Shows Anti-Inflammatory and Antidepressant-Like Effects in Mice, But Human Relevance Remains Unproven](https://cedclinic.com/cannabis-sativa-anti-inflammatory-effects-preclinical-2024/) A CED look at a preclinical mouse study of THCA- and beta-caryophyllene-rich cannabis extract, directly relevant to this review’s discussion of terpene-driven anti-inflammatory activity and the gap between animal and human evidence. [Read the preclinical anti-inflammatory study](https://cedclinic.com/cannabis-sativa-anti-inflammatory-effects-preclinical-2024/) [What the Latest Physiology Research Reveals About Cannabis Formulation and Diabetes Risk](https://cedclinic.com/cannabis-extract-vs-thc-metabolic-health/) A CED review of a Journal of Physiology study finding that whole cannabis extract, but not purified THC alone, reversed a metabolic signaling failure in an animal model, direct supporting context for this review’s entourage-effect discussion. [Read the formulation and metabolic health review](https://cedclinic.com/cannabis-extract-vs-thc-metabolic-health/) ## Frequently Asked Questions What did this review examine? A systematic review searched Scopus, Google Scholar, and PubMed for research on the non-cannabinoid phytochemicals of Cannabis sativa, terpenes, flavonoids, phenolic compounds, and alkaloids, published between January 2010 and May 2025. How many studies were included? The search initially retrieved 187 articles. After applying inclusion and exclusion criteria, 12 studies qualified for the final review. What is the entourage effect? The entourage effect, a term first proposed by Mechoulam and Ben-Shabat in 1998, describes a proposed synergistic interaction between cannabinoids and non-cannabinoid compounds like terpenes and flavonoids that may modulate overall therapeutic effects. Which non-cannabinoid compounds were best studied? Terpenes and flavonoids were the most thoroughly characterized compound classes. Studies on alkaloids and phenolic acids were comparatively sparse. Which specific compounds does the review name? Terpenes including myrcene, limonene, linalool, alpha-pinene, and beta-caryophyllene, and flavonoids including cannflavin A and B, apigenin, luteolin, kaempferol, and quercetin. What biological activities were reported? Anti-inflammatory, anti-cancer, anti-diabetic, analgesic, and antimicrobial activity were reported across different compounds in cell culture and animal-model studies. Has any of this been tested in human clinical trials? No. The review is explicit that none of the studies of isolated non-cannabinoid compounds have reached clinical trials. Most existing human data instead comes from whole-plant extracts that combine cannabinoids and non-cannabinoids together. Why hasn’t this research moved into human trials yet? The authors cite standardization challenges, regulatory barriers, and a lack of validated reference standards and analytical methods for identifying and quantifying compounds that are typically present in low concentrations. Does the cannabis strain or cultivar affect these compounds? Yes. The review cites a comparison in which the flavonoid content of one strain, Carmagnola Cs, was up to 25 percent higher than in another strain, Kompolti, illustrating how much phytochemical content can vary by cultivar. What should someone take away from this review? This review offers promising, mechanistically plausible laboratory groundwork for the entourage effect, but it is not evidence that any specific terpene, flavonoid, or full-spectrum product treats a condition in humans. Anyone weighing formulation claims should discuss them with a knowledgeable clinician. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).